🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

William Crago

Mandala Biosciences (United States)

ORCID: 0009-0000-5838-4295

Also affiliated with Inhibrx (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma”.

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0974
N/A
1.3DataRank · unranked
44 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

Data from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

(2023)10.1158/1078-0432.c.6727617.v1
N/A
0DataRank · unranked
0 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

Data from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

(2023)10.1158/1078-0432.c.6727617.v2
N/A
0DataRank · unranked
0 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more